Poehling Capital Management, Inc. Gilead Sciences, Inc. Transaction History

Poehling Capital Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 06, 2020	SELL	$62.63 - $80.22 $1.58 Million - $2.02 Million	-25,192 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $345,996 - $380,584	-5,615 Reduced 18.23%	25,192 $1.64 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $46,257 - $51,060	-740 Reduced 2.35%	30,807 $1.95 Million
Q2 2019 Aug 09, 2019	BUY	$61.87 - $69.38 $85,999 - $96,438	1,390 Added 4.61%	31,547 $2.13 Million
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $51,587 - $57,791	-825 Reduced 2.66%	30,157 $1.96 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $494,006 - $644,640	-8,160 Reduced 20.85%	30,982 $1.94 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $729,194 - $807,351	10,230 Added 35.38%	39,142 $3.02 Million
Q2 2018 Aug 08, 2018	SELL	$64.88 - $75.68 $793,158 - $925,188	-12,225 Reduced 29.72%	28,912 $2.05 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $30,592 - $37,296	-420 Reduced 1.01%	41,137 $3.1 Million
Q4 2017 Feb 13, 2018	BUY	$71.15 - $83.52 $2.96 Million - $3.47 Million	41,557	41,557 $2.98 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Poehling Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Poehling Capital Management, Inc. with notifications on news.